• Dionymer

  Participated · Seed · Feb 2026

  Founded in 2020 in Gironde, France, Dionymer develops and manufactures PolyHydroxyAlcanoates (PHA) derived from biodéchets sourced from collective catering outlets. These biopolymers serve as sustainable, fully biodegradable alternatives to the 99 % petrochemical polymers currently used in cosmetics, plastics, and paints. By valorising organic waste, the startup targets a share of the 400-million-tonne global polymer market while reducing carbon emissions and microplastic pollution. To date the company has focused on scaling its proprietary production process; the new capital will finance its transition from pure production to active commercial sales. Management emphasises that the forthcoming phase will include market entry and broader industrial deployment. Dionymer’s technology positions it for both environmental impact and regulatory tailwinds as industries seek greener materials, though no revenue or customer figures have yet been disclosed. Earlier seed financings totalled €2.5 million, and the firm is now poised to accelerate go-to-market execution with expanded manufacturing capacity.

• MilkStraw AI

  Participated · Seed · Jan 2026

  Founded in 2023 in the U.S. by Jawad Shreim and now headquartered in the UAE, MilkStraw AI provides an AI-powered cloud optimization platform that analyzes AWS usage, pinpoints savings opportunities, and automatically implements cost-saving measures for startups. The software simplifies cloud cost management, aiming to reduce spend without manual intervention. The company already serves more than 100 startups, including Thndr, Maqsam, Ziina, Beyond Limits, and Zero. Upcoming enhancements include The Feed, Right Sizing capabilities, and an AI-driven conversational interface for managing cloud infrastructure. With new capital, MilkStraw AI plans to accelerate product development and expand operations across MENA and additional international markets. The business is positioned within the fast-growing AI infrastructure SaaS and cloud optimization segment.

• Hakbah

  Participated · Series A · Jan 2024

  Hakbah digitizes traditional group savings (Jameya) into a social savings platform and offers a readily integrable savings engine that can connect with any banking system in less than a week. The product enables rotating pooled funds among members to encourage purposeful, collective saving and to improve financial inclusion and literacy. Hakbah serves Saudi Arabia's $216 billion savings market and reports a customer base of over 500,000 users, 70% of whom are aged 21–35. The company recorded an 18x increase in total savings under management and a 4x increase in revenue this year. It plans to use new capital to advance machine learning, accelerate product development, and recruit top regional talent. Hakbah also intends to enter two regional markets soon via strategic alliances or partnerships.

• Therapixel

  Participated · Series B · May 2022

  Therapixel develops MammoScreen, an AI-powered software system that assists interpretation of screening 2D and 3D (tomosynthesis) mammograms by signaling a score that indicates level of suspicion. The company holds two FDA regulatory clearances in the United States for both 2D and 3D mammography and is being deployed across large networks of breast cancer screening clinics. Therapixel’s software aims to confirm certain lesions quickly and speed reading of benign cases to save clinicians time. Led by CEO Matthieu Leclerc-Chalvet and Chief Scientific and Technology Officer and founder Pierre Fillard, the company operates from Nice/Paris, France and Chicago, IL. Therapixel plans to use new funding to accelerate its commercial presence in the United States and to launch additional features for MammoScreen. Therapixel is described as a world leader in artificial intelligence applied to radiology and was created in 2013. The company is developing an AI-based service to assist radiologists reviewing screening mammography for breast cancer. It is based in Sophia Antipolis and Paris, France. Therapixel raised €5m in a Series A financing to support its growth. The company plans to use the funds to actively recruit new talent and accelerate development. Co-founder Olivier Clatz will transition out after taking a role at the French Innovation Council, and co-founder Pierre Fillard, CTO, has been appointed interim CEO until a new chief executive joins. Therapixel provides a touchless image navigation system for interventional radiology and surgery that lets surgeons access medical images acquired before or during procedures while keeping equipment sterile. The system uses a motion sensor positioned on top of the screen to transform hand gestures into control commands. The company was founded in 2013 by Olivier Clatz and Pierre Fillard as a spin-off from Inria Sophia. Therapixel is based in Sophia Antipolis and Paris, France. It raised funding to support increased commercialization and internationalization efforts.

• Cerecin

  Participated · Series A · Oct 2021

  Cerecin focuses on creating therapeutics that address the metabolic basis of central nervous system diseases. Its lead candidate, CER-0001, is being evaluated in clinical studies for migraine prevention and infantile spasms, with plans for a pivotal Alzheimer’s disease trial. The company recently completed enrollment of the 83-patient RELIEF pilot migraine study and is expanding its infantile spasms trial sites in Australia and Singapore. Proceeds from recent financings are earmarked to advance these programs and to broaden Cerecin’s pipeline of lipid-based neurotherapeutics. Cerecin benefits from strategic backing by Nestlé S.A. and Wilmar International, along with a network of Korean institutional investors. Although no revenue figures have been disclosed, the firm closed a USD $40 million Series II/IIA round in late 2021 and continues to secure follow-on capital to reach upcoming clinical inflection points.

No current team members are available.